CS
Christopher Ryan Sullivan
Chief Financial Officer

Christopher Ryan Sullivan insider trades: Avalo Therapeutics (AVTX) stock buys and sales

Chief Financial Officer, Avalo Therapeutics Last trade Sep 16, 2026 23 Form 4 filings
$3.5M
Sold, last 12 months
6 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2020
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Christopher reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Sep 16, 2026AVTX↓ Sell$202K
Sep 10, 2026AVTX↓ Sell$179K
Aug 18, 2026AVTX↓ Sell$1.5M
May 7, 2026AVTX↓ Sell$449K
May 6, 2026AVTX↓ Sell$949K
Apr 2, 2026AVTX↓ Sell$271K
Jun 9, 2023AVTX↑ Buy$2K
Dec 10, 2021AVTX↑ Buy$1K
Dec 10, 2020CERC↑ Buy$12K
Jun 10, 2020CERC↑ Buy$7K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other AVTX insiders

Open-market trades in the last 12 months

About Christopher Ryan Sullivan's insider trades

Christopher Ryan Sullivan is Chief Financial Officer at Avalo Therapeutics (AVTX). Since Jun 10, 2020, Christopher has reported 4 open-market purchases worth $22K and 6 sales worth $3.5M on SEC Form 4. In the last 12 months: 6 sales ($3.5M).

Their filings also include grants and awards (9 filings), option exercises (7 filings), shares withheld for taxes (4 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AVTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.